News

ACC, iPad cardiology apps

DAIC readers chose the following stories as the most popular content in 2013, based on website analytics.

Sidra Medical and Research Center, a specialty women's and children's hospital in Qatar, announced that Ziyad Hijazi, M.D., has been appointed clinical chief for pediatrics.

Amplatzer, St. Jude Medical, ASD closure

The U.S. Food and Drug Administration (FDA) issued a warning this week about safety issues encountered with the St. Jude Amplatzer Atrial Septal Occluder (ASO), a transcatheter device used to seal...

August 30, 2013 — PFM Medical received U.S. Food and Drug Administration (FDA) premarket approval (PMA) for its Nit-Occlud Patent Ductus Arteriosus (PDA) device, a permanently implanted prosthesis...

Gore Helex Septal Occluder Infringement Suit Ruiling AGA Medical Corp.

W. L. Gore & Associates announced a favorable ruling involving the Gore Helex Septal Occluder. The Hon. Judge Joan Ericksen of the U.S. District Court for the District of Minnesota ruled on...

GE, TEE. amplatzer, 3D, 4D

The development of 3-D transesophageal echo (TEE) just a few years ago has enabled a new generation of interventional procedures to be performed, which otherwise would have been...

 

St. Jude Medical announced publication of results from its landmark RESPECT clinical trial in The New England Journal of Medicine.

 

St. Jude Medical has issued a Class I recall for its Amplatzer TorqVue FX Delivery System used in transcatheter closure of atrial septal defects (ASDs). The company said in a small number of cases...

Amplatzer Structural Heart Occulder Closure Device RESPECT Clinical Trial

November 8, 2012 — Results of the RESPECT clinical trial, presented at TCT 2012, indicates that using an investigational...

November 2, 2012 – A clinical trial that compared catheter-based PFO closure using an investigational device found that there was no significant reduction in ischemic and bleeding events compared...

Gore Helex Septal Occcluder REDUCE Clinical Study Cath Lab

W. L. Gore & Associates (Gore) responded to initial results reported in St. Jude Medical Inc.’s RESPECT clinical trial. The RESPECT study investigated whether transcatheter closure of patent...

Gore Helex Septal Occcluder Clinical Study

October 22, 2012 — W. L. Gore & Associates announced that the U.S. Food and Drug Administration (FDA) has approved the use of the new Gore septal...

The Transcatheter Cardiovascular Therapeutics (TCT) conference showcases key advancements being made in interventional cardiology, focusing this year on the next generation of drug-eluting stents...

Cardiac Stem Cells Regeneration Therapy Structural Heart

Researchers at the University of Maryland School of Medicine, who are exploring novel ways to treat serious heart problems in children, have conducted the first direct comparison of the...

June 18, 2012 — St. Jude Medical Inc. announced it has received U.S. Food and Drug Administration (FDA) clearance and will immediately launch the Amplatzer Vascular Plug 4 (AVP 4) for use in...

May 31, 2012 —Occlutech GmbH, the leading European developer of minimally invasive implants for the treatment of structural heart disease, announced receiving a favorable Supreme Court ruling from...

April 24, 2012 - SeptRx, an emerging medical device company that has developed the SeptRx Intrapocket PFO Occluder (IPO) — a platform for the percutaneous transcatheter closure of a heart defect...

November 15, 2011 – Results of the PARTNER Cohort A QOL study demonstrate that transcatheter aortic valve replacement (TAVR) results in improved quality of life compared with surgical valve...

November 4, 2011 – W. L. Gore & Associates announced that Royal Sussex County Hospital in Brighton, United Kingdom, is the first medical center in the United Kingdom to enroll a patient in the...

October 19, 2011— W. L. Gore and Associates announced that the company purchased the assets and intellectual property of now defunct company NMT Medical Inc. The purchase included the data related...